Malnutrition in Cirrhosis: Frequent but Overlooked
Gabriela Kuftinec, Kalyan Ram Bhamidimarri, Michelle Pearlman – 14 October 2019
Transient Cold Storage Prior to Normothermic Liver Perfusion May Facilitate Adoption of a Novel Technology
Davide Ghinolfi, Daniele Pezzati, Erjon Rreka, Giandomenico Biancofiore, Paolo De Simone – 14 October 2019
Nonalcoholic Steatohepatitis After Liver Transplantation
Thomas G. Cotter, Michael Charlton – 14 October 2019 – Currently, nonalcoholic steatohepatitis (NASH) is the second leading indication for liver transplantation (LT), behind alcohol‐related liver disease. After transplant, both recurrent and de novo nonalcoholic fatty liver disease are common; however, recurrence rates of NASH and advanced fibrosis are low. Identification of high‐risk groups and optimizing treatment of metabolic comorbidities both before and after LT is paramount to maintaining a healthy allograft, especially with the additional consequences of longterm immunosuppression.
Tuberculosis Treatment With a 3‐Drug Rifamycin‐Free Regimen in Liver Transplant Recipients
Timothy Sullivan, Samantha Jacobs, Jennifer Leong, Dallas Dunn, Emily Baneman, Sarah Taimur, Shirish Huprikar, Meenakshi Rana – 13 October 2019
Everolimus: Longer‐Term CERTITUDE
Omar Y. Mousa, Andrew P. Keaveny – 13 October 2019
Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure
Manuel Mendizabal, Marcelo Dip, Ezequiel Demirdjian, Leandro Lauferman, Susana Lopez, Julia Minetto, Alejandro Costaguta, Carolina Rumbo, Ivone Malla, María Camila Sanchez, Esteban Halac, Guillermo Cervio, Miriam Cuarterolo, Marcela Galoppo, Oscar Imventarza, Liliana Bisgniano, Daniel D’Agostino, Fernando Rubinstein – 13 October 2019 – After the implementation of universal hepatitis A virus vaccination in Argentina, the outcome of pediatric acute liver failure (PALF) remains unknown.
Novel Arterial Reconstruction With Donor Femoral Artery in Split‐Liver Transplantation
Flavio Paterno, Lloyd Brown, Dorian Wilson, Nikolaos Pyrsopoulos, James V. Guarrera – 12 October 2019
Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis
Ashley M. Hyde, Michelle Carbonneau, Juan G. Abraldes, Puneeta Tandon – 12 October 2019
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin – 10 October 2019 – In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown.
Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice
Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Sharon C. Cunningham, Alexandra Sharland, Ian E. Alexander, Peter W. Angus, Chandana B. Herath – 10 October 2019 – There is a large unmet need for effective therapies for cholestatic disorders, including primary sclerosing cholangitis (PSC), a disease that commonly results in liver failure. Angiotensin (Ang) II of the renin Ang system (RAS) is a potent profibrotic peptide, and Ang converting enzyme 2 (ACE2) of the alternate RAS breaks down Ang II to antifibrotic peptide Ang‐(1‐7).